Engineered Stem Cells Delivering sTRAIL for Brain Metastases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for metastatic brain tumors face challenges due to the blood-brain barrier and negative side effects of radiotherapy, limiting their effectiveness in treating multifocal metastases in the brain.
Innovation Solution
Engineered stem cells, such as mesenchymal or neuronal stem cells, are used to express a soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) polypeptide, which is administered intracarotidly to target and inhibit the growth of multifocal metastases in the brain, potentially combined with a prodrug-converting enzyme like HSV thymidine kinase for post-treatment eradication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies (chemotherapy, radiotherapy) are used to treat metastatic brain tumors, then tumor treatment is attempted, but the blood-brain barrier prevents effective drug penetration and radiotherapy causes negative side effects
Solution Approach 1:
The patent uses engineered stem cells as intermediary carriers that can traverse the blood-brain barrier and deliver therapeutic agents (sTRAIL polypeptides) directly to tumor sites. The stem cells act as a mediator between the therapeutic agent and the target tumor, overcoming the barrier obstruction problem while reducing systemic side effects.
Solution Approach 2:
The stem cells are engineered to autonomously navigate to tumor sites using their natural tropism for brain tissue and tumor microenvironments. They self-direct to multifocal metastases without requiring external guidance, delivering therapy precisely where needed while avoiding healthy brain tissue to minimize side effects.
2Productivity
If surgery is used to treat multiple metastatic lesions, then some tumors can be removed, but surgery is inadequate for multifocal metastases
Solution Approach 1:
The engineered stem cell therapy provides a universal treatment approach that can simultaneously address multiple metastatic lesions throughout the brain. Unlike surgery which must address lesions individually, the stem cells circulate and target all tumor sites systemically, making the therapy adaptable to multifocal disease patterns.
3Reliability
If stem cells are engineered to express sTRAIL for tumor targeting, then tumor growth is inhibited, but the stem cells remain in the body post-treatment
Solution Approach 1:
The patent incorporates a suicide gene (HSV thymidine kinase) into the engineered stem cells that allows for controlled elimination of the cells after they have completed their therapeutic function. This enables the discarding of the engineered cells post-treatment while maintaining the beneficial tumor-killing effects during treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach allows for targeted treatment of multifocal brain metastases, suppressing tumor growth and prolonging survival by exploiting tumor-specific biomarkers and apoptosis pathways, while enabling the eradication of treated stem cells post-treatment.
Implementation Method 1
tumor necrosis factor-related apoptosis inducing ligand (sTRAIL) polypeptides
Implementation Method 2
binding agent specific for a tumor-associated cell-surface protein, whereby the growth and/or survival of multifocal metastases in the brain is/are inhibited
Implementation Method 3
potentially combined with a prodrug-converting enzyme like HSV thymidine kinase for post-treatment eradication
Data Source
Figure 1A~1B
Figure 1C
Figure 1D
AI summary
Compositions and methods are provided comprising soluble TRAIL polypeptide agents and cells engineered to express such agents for the treatment of multifocal brain metastases.